Covid-19
Covid vaccine kills Braveheart actor six days after third Pfizer “booster” shot
The dangers of covid vaccines have continued to spread across the world, causing more harm than the virus the vaccines were meant to prevent or cure.
A Braveheart actor, Michael Mitchell, was declared dead six days after receiving the Pfizer “booster” injection for COVID-19.
There have been arguments over the efficacy of the Pfizer vaccine in the prevention of coronavirus infection. Several cases have been reported on adverse effects of covid vaccines; more especially, as many who received two shots of vaccine were detected to have suffered covid infection. Producers of Pfizer in the debate recommended a third jab described as a “booster” shot.
Meanwhile, Pfizer disclosed the distribution of over one billion doses of vaccine, targeting to distribute two billion doses by 2022 and five billion in the subsequent year.
Mitchel was said to have received the first two jabs of Sinovac; he was said to be afraid, expressing fear that he didn’t want to contact the “delta variant.” The Braveheart actor was pushed by fear to get the third injection; however, taking the Pfizer ‘booster’ shot. Mitchel died a few days away.
Mitchell was said to have died in the marina cabin near the house after the injection.
-
Latest1 week agoLagos NURTW organising secretary Toba Ajiboye dies after gunmen attack
-
Business5 days agoCBN targets $12bn annual Diaspora inflows to boost FX liquidity
-
Business5 days agoSEC launches nationwide campaign to help investors recover unclaimed dividends
-
Business4 days agoNigerian AI researcher champions ethical artificial intelligence at COPA AI 2026 summit in Wales
-
Latest1 week agoOyo APC berates Makinde over call for UN probe into Oriire school rescue
-
Business6 days agoCBN launches real-time FX tracker for BDCs, tightens oversight of FX market
-
Latest7 days agoKwankwaso calls for renewed North–South-East Political alliance ahead of 2027
-
Business5 days agoFood prices now biggest threat to inflation, beyond CBN’s reach – Analysts


